Literature DB >> 11452979

Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons.

S Erhardt1, H Oberg, J M Mathé, G Engberg.   

Abstract

Inhibitors of kynurenine 3-hydroxylase have previously been used to increase endogenous levels of kynurenic acid, an excitatory amino acid receptor antagonist. In the present electrophysiological study PNU 156561A was utilized to elevate endogenous concentrations of kynurenic acid and subsequent effects on the firing pattern of dopamine (DA) neurons of rat substantia nigra (SN) were analyzed. Pretreatment with PNU 156561A (40 mg/kg, i.v., 5-7 h) caused a five-fold increase in endogenous kynurenic acid levels in whole brain five to seven hours after administration and also evoked a significant increase in firing rate and bursting activity of nigral DA neurons. The results of the present study show that a moderate increase in endogenous kynurenic acid levels produces significant actions on the tonic glutamatergic control of the firing pattern of nigral DA neurons, and implicate kynurenine 3-hydroxylase inhibitors as novel antiparkinsonian agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11452979     DOI: 10.1007/s007260170032

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  25 in total

1.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

Authors:  Klas R Linderholm; Elisabeth Skogh; Sara K Olsson; Marja-Liisa Dahl; Maria Holtze; Göran Engberg; Martin Samuelsson; Sophie Erhardt
Journal:  Schizophr Bull       Date:  2010-08-20       Impact factor: 9.306

2.  Kynurenine is correlated with IL-1β in plasma of schizophrenia patients.

Authors:  Helena P G Joaquim; Alana C Costa; Wagner F Gattaz; Leda Leme Talib
Journal:  J Neural Transm (Vienna)       Date:  2018-01-06       Impact factor: 3.575

3.  Inhibition of Large Neutral Amino Acid Transporters Suppresses Kynurenic Acid Production Via Inhibition of Kynurenine Uptake in Rodent Brain.

Authors:  Airi Sekine; Yusuke Kuroki; Tomomi Urata; Noriyuki Mori; Tsutomu Fukuwatari
Journal:  Neurochem Res       Date:  2016-05-09       Impact factor: 3.996

Review 4.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

Review 5.  [Immunology in schizophrenic disorders].

Authors:  N Müller; M J Schwarz
Journal:  Nervenarzt       Date:  2007-03       Impact factor: 1.214

6.  Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?

Authors:  H-Q Wu; A Rassoulpour; R Schwarcz
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

Review 7.  Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.

Authors:  N Muller; M Schwarz
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

8.  Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder.

Authors:  Sara K Olsson; Martin Samuelsson; Peter Saetre; Leif Lindström; Erik G Jönsson; Conny Nordin; Göran Engberg; Sophie Erhardt; Mikael Landén
Journal:  J Psychiatry Neurosci       Date:  2010-05       Impact factor: 6.186

9.  Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia.

Authors:  Maximilian Tufvesson-Alm; Lilly Schwieler; Robert Schwarcz; Michel Goiny; Sophie Erhardt; Göran Engberg
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

Review 10.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.